Actively Recruiting

Phase 2
Age: 12Years +
All Genders
NCT07399704

A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

Led by Azafaros A.G. · Updated on 2026-05-07

21

Participants Needed

3

Research Sites

235 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This open-label study aims to gather long-term safety, tolerability, PK, biomarker, and clinical efficacy data relating to daily administration of Nizubaglustat in participants previously enrolled in the Phase 2 RAINBOW study (Cohort 1). In addition, the study aims to assess safety, clinical, and biochemical impact of transitioning NPC disease patients to Nizubaglustat after prior treatment with stable, full-dose Miglustat (Cohort 2).

CONDITIONS

Official Title

A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Have been randomized into Phase 2 Study AZA-001-5A2-01 (RAINBOW) for Cohort 1
  • Be male or female aged 12 years or older for Cohort 2
  • Have genetically confirmed Niemann-Pick Type C disease for Cohort 2
  • Have received full-dose Miglustat treatment for at least 12 months for Cohort 2
  • Have stable or worsening disease over the 2 previous clinic visits while on Miglustat for Cohort 2
  • Wish to change treatment to Nizubaglustat for NPC disease for Cohort 2
  • Be willing and able to complete all protocol assessments
  • Participant, parent, or legal guardian can read, understand, and sign informed consent; assent obtained if applicable
Not Eligible

You will not qualify if you...

  • Positive serum pregnancy test (for women of childbearing potential)
  • Female planning to breastfeed during the study
  • Any medical condition or event that prevents participation as judged by the Principal Investigator
  • Participation in another interventional or non-interventional study or early access program

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Associação Hospitalar de Prot à Infância Dr. Raul Carneiro

Água Verde, Curitiba, Brazil, 80250-060

Actively Recruiting

2

Hospital de Clinicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil, 90035-903

Actively Recruiting

3

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira

Rio de Janeiro, Brazil, 22250

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here